This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period. Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
All 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks.
Citruslabs
Las Vegas, Nevada, United States
Change in Gastrointestinal Symptom Rating Scale (GSRS)
Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity.
Time frame: Baseline to Week 12
Change in Self-Reported Energy Level Score
Change from baseline to Week 12 in participant-reported energy level, as assessed using the study questionnaire.
Time frame: Baseline to Week 12
Change in Self-Reported Brain Fog Score
Change from baseline to Week 12 in participant-reported brain fog, as assessed using the study questionnaire.
Time frame: Baseline to Week 12
Change in Self-Reported Mood Stability Score
Change from baseline to Week 12 in participant-reported mood stability, as assessed using the study questionnaire.
Time frame: Baseline to Week 12
Change in Self-Reported Sleep Quality Score
Change from baseline to Week 12 in participant-reported sleep quality, as assessed using the study questionnaire.
Time frame: Baseline to Week 12
Change in Self-Reported Skin Clarity Score
Change from baseline to Week 12 in participant-reported skin clarity, as assessed using the study questionnaire.
Time frame: Baseline to Week 12
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)
Incidence, severity, and relationship to study product of treatment-emergent adverse events occurring from the first dose of study product through the end of the 12-week study period.
Time frame: Continuous monitoring over 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.